

Yago Nieto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/495168/publications.pdf>

Version: 2024-02-01

160
papers

3,944
citations

185998

28
h-index

149479

56
g-index

162
all docs

162
docs citations

162
times ranked

5588
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. <i>New England Journal of Medicine</i> , 2020, 382, 545-553.	13.9	1,252
2	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 457-466.	1.2	158
3	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019, 134, 22-29.	0.6	129
4	Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 175-182.	0.4	110
5	Prognostic Significance of Overexpression and Phosphorylation of Epidermal Growth Factor Receptor (EGFR) and the Presence of Truncated EGFRvIII in Locoregionally Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4405-4413.	0.8	84
6	Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 901-923.	1.5	84
7	Results of a 2â€arm, phase 2 clinical trial using postâ€transplantation cyclophosphamide for the prevention of graftâ€versusâ€host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. <i>Cancer</i> , 2016, 122, 3316-3326.	2.0	75
8	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Bloodâ€Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 3744-3756.	3.2	69
9	Autologous Stem Cell Transplantation for Refractory orâ€Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of theâ€Specific High-Dose Chemotherapy Regimen onâ€Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 410-417.	2.0	61
10	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamideâ€Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
11	CRP and ferritin in addition to the EASIX score predict CAR-Tâ€related toxicity. <i>Blood Advances</i> , 2021, 5, 2799-2806.	2.5	57
12	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. <i>Blood</i> , 2016, 128, 297-312.	0.6	54
13	Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 113-121.	0.4	50
14	Double epigenetic modulation of highâ€dose chemotherapy with azacitidine and vorinostat for patients with refractory or poorâ€risk relapsed lymphoma. <i>Cancer</i> , 2016, 122, 2680-2688.	2.0	48
15	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1914-1920.	2.0	46
16	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 122-126.	2.5	46
17	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45
18	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	3.4	44

#	ARTICLE	IF	CITATIONS
19	High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1677-1686.	2.0	43
20	Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. <i>Experimental Hematology</i> , 2012, 40, 800-810.	0.2	41
21	Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 412-420.	2.0	40
22	Impact of TKIs postâ€“allogeneic hematopoietic cell transplantation in Philadelphia chromosomeâ€“positive ALL. <i>Blood</i> , 2020, 136, 1786-1789.	0.6	40
23	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 906-912.	2.0	35
24	Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. <i>Oncotarget</i> , 2018, 9, 3908-3921.	0.8	35
25	Post-Transplant Outcomes in High-Risk Compared with Nonâ€“High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
26	Better allele-level matching improves transplant-related mortality after double cord blood transplantation. <i>Haematologica</i> , 2015, 100, 1361-1370.	1.7	32
27	Leukemia cell mobilization with G-CSF plus plerixafor during busulfanâ€“fludarabine conditioning for allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 939-946.	1.3	32
28	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2710-2719.	0.8	32
29	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.	2.0	31
30	Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. <i>Oncotarget</i> , 2018, 9, 35611-35622.	0.8	31
31	Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 687-693.	0.2	29
32	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	2.5	28
33	Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. <i>Cancer</i> , 2016, 122, 3831-3837.	2.0	27
34	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	3.3	27
35	High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?. <i>Current Opinion in Oncology</i> , 2009, 21, 150-157.	1.1	24
36	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 285-292.	2.0	24

#	ARTICLE	IF	CITATIONS
37	Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 530-540.	0.4	23
38	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e532-e542.	2.2	23
39	Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin,) Tj ETQq1 1 0.784314 rgBT /O 863-870.	0.6	22
40	The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e1-e5.	0.2	21
41	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 665-671.	2.0	21
42	Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1333-1337.	2.0	19
43	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. <i>Lancet Haematology</i> , 2017, 4, e283-e292.	2.2	19
44	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
45	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). <i>Bone Marrow Transplantation</i> , 2022, 57, 51-56.	1.3	19
46	A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1453-1458.	2.0	18
47	A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Cancer</i> , 2017, 123, 1363-1371.	2.0	18
48	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
49	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 430.e1-430.e7.	0.6	18
50	Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 60-66.	2.0	17
51	Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e41-e50.	0.2	17
52	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1439-1445.	2.0	17
53	Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. <i>Blood</i> , 2018, 131, 1248-1257.	0.6	16
54	Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. <i>Oncotarget</i> , 2016, 7, 63829-63838.	0.8	16

#	ARTICLE	IF	CITATIONS
55	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 961-965.	2.0	15
56	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1602-1609.	2.0	15
57	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1146-1154.	0.4	15
58	A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. <i>Haematologica</i> , 2018, 103, e416-e418.	1.7	15
59	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. <i>Leukemia and Lymphoma</i> , 2019, 60, 442-452.	0.6	15
60	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 505-514.	2.0	15
61	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	2.0	15
62	Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. <i>Haematologica</i> , 2021, 106, 3211-3214.	1.7	13
63	Phase I and Pharmacokinetic Study of Gemcitabine Administered at Fixed-Dose Rate, Combined with Docetaxel/Melphalan/Carboplatin, with Autologous Hematopoietic Progenitor-Cell Support, in Patients with Advanced Refractory Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1324-1337.	2.0	12
64	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 122-128.	0.2	12
65	A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-Hodgkin lymphomas: long term results. <i>British Journal of Haematology</i> , 2017, 178, 561-570.	1.2	12
66	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1099-1106.	2.0	12
67	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 272.e1-272.e5.	0.6	12
68	Stem cell transplantation outcomes in lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 366-371.	0.6	11
69	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. <i>Cancer</i> , 2017, 123, 3568-3575.	2.0	11
70	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥ 75 years. <i>Leukemia and Lymphoma</i> , 2019, 60, 3536-3543.	0.6	11
71	Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e124-e127.	0.2	11
72	Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. <i>Blood Advances</i> , 2020, 4, 4834-4837.	2.5	11

#	ARTICLE	IF	CITATIONS
73	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 6781-6787.	3.2	10
74	Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1003.e1-1003.e13.	0.6	10
75	Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 843-849.	2.0	9
76	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 639-646.	0.6	9
77	Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e221-e238.	0.2	9
78	Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. <i>British Journal of Haematology</i> , 2021, 192, 560-567.	1.2	9
79	Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. <i>Haematologica</i> , 2022, 107, 899-908.	1.7	9
80	Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 3155-3155.	0.6	9
81	Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. <i>Experimental Hematology</i> , 2020, 81, 32-41.	0.2	8
82	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2022, 63, 710-721.	0.6	8
83	Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. <i>Experimental Hematology</i> , 2016, 44, 458-465.	0.2	7
84	Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. <i>Leukemia and Lymphoma</i> , 2016, 57, 2644-2652.	0.6	7
85	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1340-1346.	2.0	7
86	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. <i>Blood Advances</i> , 2020, 4, 1296-1306.	2.5	7
87	Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Clinical Studies, and MD Anderson. <i>Blood</i> , 2019, 134, 1931-1931.	0.6	7
88	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	0.6	7
89	KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1142-1149.	1.3	7
90	The Emerging Role of Gemcitabine in Conditioning Regimens for Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1382-1389.	2.0	6

#	ARTICLE	IF	CITATIONS
91	Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. <i>Transfusion</i> , 2017, 57, 1052-1057.	0.8	6
92	The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. <i>Leukemia and Lymphoma</i> , 2017, 58, 2705-2716.	0.6	6
93	Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 263-268.	1.1	6
94	Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. <i>Annals of Hematology</i> , 2019, 98, 2233-2235.	0.8	6
95	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 913.e1-913.e12.	0.6	6
96	Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2270-2270.	0.6	6
97	Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. <i>Blood Advances</i> , 2022, 6, 2267-2274.	2.5	6
98	ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells. <i>Oncotarget</i> , 2022, 13, 319-330.	0.8	6
99	Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 395.e1-395.e11.	0.6	6
100	Progressive Multifocal Leukoencephalopathy After Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1660-1664.	2.3	5
101	Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. <i>Leukemia Research</i> , 2016, 47, 100-108.	0.4	5
102	Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 445-447.	0.6	5
103	Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1276-1281.	2.0	5
104	Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. <i>Journal of Cancer</i> , 2017, 8, 1009-1017.	1.2	5
105	Melphalan-based autologous transplant in octogenarian multiple myeloma patients. <i>American Journal of Hematology</i> , 2019, 94, E2-E5.	2.0	5
106	A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. <i>Blood</i> , 2012, 120, 4200-4200.	0.6	5
107	Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). <i>Blood</i> , 2013, 122, 410-410.	0.6	5
108	Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. <i>Blood</i> , 2013, 122, 5356-5356.	0.6	5

#	ARTICLE	IF	CITATIONS
109	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. <i>Blood</i> , 2015, 126, 854-854.	0.6	5
110	High-Dose Chemotherapy with Autologous Stem Cell Transplant for Breast Cancer: What Have We Learned 25 Years Later?. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 3-5.	2.0	4
111	Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1529-1531.	2.0	4
112	Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. <i>American Journal of Hematology</i> , 2018, 94, E72-E74.	2.0	4
113	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1077-1083.	2.0	4
114	Plasmablastic Lymphoma: 28 Patient Single Institution Experience. <i>Blood</i> , 2013, 122, 4310-4310.	0.6	4
115	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	0.6	4
116	Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 501.e1-501.e7.	0.6	4
117	Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1059-1063.	2.0	3
118	Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. <i>British Journal of Haematology</i> , 2021, 192, e115-e120.	1.2	3
119	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 404.e1-404.e5.	0.6	3
120	Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity score matched analysis. <i>American Journal of Hematology</i> , 2021, 96, E455-E457.	2.0	3
121	Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. <i>Blood</i> , 2016, 128, 5628-5628.	0.6	3
122	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	3
123	Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. <i>Journal of Medical Case Reports</i> , 2016, 10, 209.	0.4	2
124	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2021, 144, 74-81.	0.7	2
125	Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. <i>Leukemia and Lymphoma</i> , 2022, 63, 1634-1644.	0.6	2
126	Phase II study of umbilical cord blood-derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8009-8009.	0.8	2

#	ARTICLE	IF	CITATIONS
127	Transplantation for Refractory Germ Cell Tumors: Does it Really Make a Difference?. <i>Current Oncology Reports</i> , 2013, 15, 232-238.	1.8	1
128	Incidence and predictors of Lhermitteâ€™s sign among patients receiving mediastinal radiation for lymphoma. <i>Radiation Oncology</i> , 2015, 10, 206.	1.2	1
129	Letter to the Editor Regarding â€œHarmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statementâ€. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e232-e234.	2.0	1
130	Prolonged neurotoxicity in a lymphoma patient after CD19â€directed CAR Tâ€cell therapy: A case report and brief review of the literature. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, e104.	0.6	1
131	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 243.e1-243.e6.	0.6	1
132	Polyoma (BK) Viruria Prior to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) from Donors Other Than Matched Siblings: A Prospective Evaluation of Hemorrhagic Cystitis (HC) Incidence. <i>Blood</i> , 2008, 112, 50-50.	0.6	1
133	Increased Bone Marrow Plasma Cell Infiltration Pre-Transplant Is Associated with Worse Outcomes in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma,. <i>Blood</i> , 2011, 118, 4135-4135.	0.6	1
134	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleuce (axi-cel) for Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 17-18.	0.6	1
135	African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. <i>Blood</i> , 2020, 136, 9-10.	0.6	1
136	Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 24-25.	0.6	1
137	Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7536-7536.	0.8	1
138	Mismatches in Low Expression HLA Class II Loci and MIC-A in Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT).. <i>Blood</i> , 2007, 110, 3050-3050.	0.6	0
139	Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.. <i>Blood</i> , 2007, 110, 48-48.	0.6	0
140	Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. <i>Blood</i> , 2008, 112, 799-799.	0.6	0
141	Early Mixed Chimerism After Allogeneic Stem Cell Transplantation with the Reduced-Toxicity IV Busulfan-Fludarabine (BuFlu) Regimen Does Not Independently Affect Long-Term Prognosis for Patients with AML/MDS.. <i>Blood</i> , 2010, 116, 3446-3446.	0.6	0
142	Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. <i>Blood</i> , 2010, 116, 2341-2341.	0.6	0
143	Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. <i>Blood</i> , 2011, 118, 2006-2006.	0.6	0
144	Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblastic Leukemia (ALL) With First Complete Remission (CR). <i>Blood</i> , 2013, 122, 2142-2142.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3358-3358.	0.6	0
146	Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4517-4517.	0.8	0
147	Autologous stem cell transplantation in dialysis-dependent myeloma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8601-8601.	0.8	0
148	Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8538-8538.	0.8	0
149	The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. <i>Blood</i> , 2015, 126, 3984-3984.	0.6	0
150	Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2276-2276.	0.6	0
151	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 4667-4667.	0.6	0
152	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. <i>Blood</i> , 2018, 132, 4607-4607.	0.6	0
153	Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. <i>Blood</i> , 2021, 138, 1802-1802.	0.6	0
154	Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 1779-1779.	0.6	0
155	A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021, 138, 3941-3941.	0.6	0
156	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
157	Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 23-24.	0.6	0
158	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 40-41.	0.6	0
159	Hematopoietic Cell Transplantation for Breast Cancer. , 0, , 931-947.		0
160	Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20024-e20024.	0.8	0